Inhibrx Files For IPO
socalTECH
JUNE 4, 2019
La Jolla-based biopharmaceuticals startup Inhibrx has just filed for an IPO, saying in an S-1 filing that it is looking to raise up to $74.75M in an IPO on the Nasdaq Global Market. The company reported a net loss of $31.02M in 2018 on revenues of $8.5M; the company's current revenue stream includes both license fees and grants.
Let's personalize your content